Takehiko Kamijo

11PUBLICATIONS
24CO-AUTHORS
Molecular targetsPredictive and prognostic markersNeurology and neuromuscular diseasesHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Nov 13, 2025
Synthetic lethality of EZH2 and DNMT Inhibition suppresses neuroblastoma proliferation via MYCN destabilization.

Yuki Endo, Ryuichi P Sugino, Hisanori Takenobu

|Aug 27, 2024
L3MBTL2 maintains MYCN-amplified neuroblastoma cell proliferation through silencing NRIP3 and BRME1 genes.

Ryu Okada, Hisanori Takenobu, Shunpei Satoh

|Apr 05, 2024
A nationwide phase II study of delayed local treatment for children with high-risk neuroblastoma: The Japan Children's Cancer Group Neuroblastoma Committee Trial JN-H-11.

Akihiro Yoneda, Hiroyuki Shichino, Tomoro Hishiki

|Oct 27, 2023
Minimal Residual Disease Detected by the 7NB-mRNAs ddPCR Assay Is Associated with Disease Progression in High-Risk Neuroblastoma Patients: A Prospective Multicenter Observational Study in Japan.

Noriyuki Nishimura, Toshiaki Ishida, Isao Yokota

|May 27, 2023
DNA Ligase 4 Contributes to Cell Proliferation against DNA-PK Inhibition in MYCN-Amplified Neuroblastoma IMR32 Cells.

Kiyohiro Ando, Yusuke Suenaga, Takehiko Kamijo

|Jan 20, 2023
Development of an osteosarcoma model with MYCN amplification and TP53 mutation in hiPS cell-derived neural crest cells.

Kyosuke Mukae, Hisanori Takenobu, Yuki Endo

Pageof 2

Frequent Collaborators

6 joint publications

Miki Ohira

4 joint publications

Kyosuke Mukae

3 joint publications

Yuki Endo

2 joint publications

Hisanori Takenobu